J. Brahmer

发表

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Ami A. Shah, K. F. Moseley, E. Lipson, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

J. Szustakowski, K. O'Byrne, S. Ramalingam, 2018, The New England journal of medicine.

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

J. Verweij, S. Baker, A. Sparreboom, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

C. Drake, P. Hwu, A. Korman, 2012, The New England journal of medicine.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

L. Crinò, J. Aerts, E. Vokes, 2015, The New England journal of medicine.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

R. Scharpf, M. Brock, V. Velculescu, 2018, Cancer research.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

C. Rudin, S. Gettinger, E. Felip, 2015, The New England journal of medicine.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Y. Shentu, A. Tafreshi, M. O'Brien, 2016, The New England journal of medicine.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

C. Zahnow, S. Baylin, R. Scharpf, 2017, Cancer discovery.

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA

V. Velculescu, L. Diaz, M. Popoli, 2016, Clinical Cancer Research.

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Charles G. Drake, C. Drake, E. Lipson, 2014, Nature Reviews Clinical Oncology.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity

Ludmila V. Danilova, L. Cope, V. Velculescu, 2018, Cancer Immunology Research.

Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer

Stephen Broderick, John-William Sidhom, Valsamo Anagnostou, 2018, The New England journal of medicine.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

David C. Smith, A. Drilon, J. Wolchok, 2019, JAMA oncology.

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

David R. Jones, V. Velculescu, J. Taube, 2019, Clinical Cancer Research.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

V. Velculescu, J. Taube, J. Wolchok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Israel Lowy, Mark Selby, Drew M Pardoll, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

Manuel Hidalgo, Ming Zhao, Mats O Karlsson, 2006, Journal of the National Cancer Institute.

CYP 3 A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

M. Hidalgo, M. Karlsson, S. Baker, 2022 .

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

S. Baylin, R. Scharpf, D. Ettinger, 2020, Nature Cancer.

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

S. Gettinger, E. Felip, E. Vokes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

R. Hales, D. Ettinger, L. Yarmus, 2021, JTO clinical and research reports.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review

J. Brahmer, Paola Ghanem, R. Naik, 2021, Annals of Hematology.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

L. Schwartz, R. Govindan, J. Neal, 2018, Journal of Immunotherapy for Cancer.

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2015 .

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

S. Gettinger, F. Shepherd, D. Gerber, 2016 .

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).

S. Gettinger, F. Shepherd, D. Gerber, 2013 .

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

N. Segal, M. Maio, S. Antonia, 2014 .

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

J. Sosman, M. Dwyer, B. Kaffenberger, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

J. Riess, J. Brahmer, A. Calles, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

R. Hales, D. Ettinger, L. Yarmus, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

C. Lin, R. Hales, D. Ettinger, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

S. Armato, P. Jänne, Helen X. Chen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

Carboplatin in the Treatment of Small Cell Lung Cancer

D. Ettinger, J. Brahmer, 1998 .

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Matthew J. Frigault, M. Wahidi, J. Sosman, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

David R. Jones, V. Rusch, S. Broderick, 2019, The Journal of thoracic and cardiovascular surgery.

Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come.

J. Herman, S. Baylin, D. Ettinger, 2005, The Journal of thoracic and cardiovascular surgery.

32 – Pleural and pericardial effusions

A. Balmanoukian, J. Brahmer, 2011 .

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

H. Wakelee, J. Schiller, C. Langer, 2012, Lung cancer.

Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report

G. Giaccone, D. Ettinger, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

T. Lynch, A. Wozniak, Priya Kumar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature

R. Hales, R. Yung, Sean X. Zhang, 2019, BMC Infectious Diseases.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

M. Suarez‐Almazor, J. Wolchok, M. Atkins, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.

J. Chaft, A. Rimner, J. Friedberg, 2007, Translational lung cancer research.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

J. Schiller, A. Sandler, J. Brahmer, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of malignant pleural effusion

J. Brahmer, Hongbin Chen, 2008, Current oncology reports.

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

C. Rudin, M. Borad, P. LoRusso, 2011, Clinical Cancer Research.

Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.

M. Edelman, L. Doyle, J. Brahmer, 2008, Lung cancer.

DynamicsofTumorand ImmuneResponsesduring Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

R. Scharpf, M. Brock, V. Velculescu, 2019 .

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Ami A. Shah, E. Lipson, C. Bingham, 2018, Seminars in arthritis and rheumatism.

Harnessing the immune system for the treatment of non-small-cell lung cancer.

J. Brahmer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

David C. Smith, J. Wolchok, C. Drake, 2010 .

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Robert Gray, R. Gray, J. Schiller, 2006, The New England journal of medicine.

Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.

T. Lynch, A. Wozniak, D. Spigel, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

V. Seshan, C. Rudin, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meaningful Subset Analyses Contribute to Optimal Patient Care

R. Gray, S. Ramalingam, J. Schiller, 2008 .

Second-line therapy for advanced non-small-cell lung cancer

J. Brahmer, C. Hann, 2006, Current oncology reports.

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

M. Hidalgo, S. Baker, W. Messersmith, 2006, Investigational New Drugs.

C-fos assessment as a marker of anti-epidermal growth factor receptor effect.

A. Jimeno, M. Hidalgo, D. Clark, 2006, Cancer research.

Update in Oncology

J. Brahmer, 2005, Annals of Internal Medicine.

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Thomas J. Smith, G. Giaccone, N. Hanna, 2017, Journal of oncology practice.

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

362 Binding of gefitinib (ZD1839) to human plasma proteins: in vitro and clinical pharmacokinetic (PK) studies

M. Hidalgo, S. Baker, W. Messersmith, 2004 .

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

L. Crinò, N. Rizvi, M. Hellmann, 2016 .

Adjuvant treatment in non-small cell lung cancer: Where are we now?

J. Brahmer, R. Juergens, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical Significance of Plasma CD9-Positive Exosomes in HIV Seronegative and Seropositive Lung Cancer Patients

S. Baylin, M. Brock, Beverly Lee, 2021, Cancers.

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

N. Rizvi, S. Antonia, J. Brahmer, 2014 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

C. Lin, P. Illei, J. Feliciano, 2021, Journal for ImmunoTherapy of Cancer.

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2013 .

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2018 .

Immunotherapy for Lung Cancer: No Longer an Abstract Concept

J. Naidoo, J. Brahmer, K. Marrone, 2016, Seminars in Respiratory and Critical Care Medicine.

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

V. Velculescu, Q. K. Li, V. Anagnostou, 2022, Journal for ImmunoTherapy of Cancer.

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

M. Stockler, N. Pavlakis, K. O'Byrne, 2022, BMJ Open.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

Ami A. Shah, E. Lipson, J. Albayda, 2017, The oncologist.

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

A. Wozniak, E. Felip, J. Chaft, 2018 .

Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC).

M. Ostland, R. Gray, J. Schiller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

E. Felip, L. Crinò, N. Rizvi, 2016 .

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

S. Broderick, T. Mitsudomi, Changli Wang, 2021, Clinical Trials.

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

L. Urban, K. O'Byrne, Keunchil Park, 2021 .

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

C. Lin, R. Hales, D. Ettinger, 2019, Clinical lung cancer.

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

N. Girard, S. Broderick, T. Mitsudomi, 2021 .

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

J. Brahmer, C. Lacchetti, John A Thompson, 2018, Journal of oncology practice.

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

C. Bettegowda, E. Lipson, W. Sharfman, 2017, International journal of radiation oncology, biology, physics.

OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer

A. Tafreshi, M. O'Brien, J. Brahmer, 2019, Journal of Thoracic Oncology.

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

H. Borghaei, J. Brahmer, 2016, The New England journal of medicine.

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

D. Ettinger, R. Karchin, V. Anagnostou, 2022, Frontiers in Oncology.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

C. Lin, D. Ettinger, L. Yarmus, 2019, The Journal of clinical investigation.

Pleural mesothelioma metastatic to tongue.

D. Higginson, J. Brahmer, R. Tufano, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies-Final results.

A. Jimeno, M. Hidalgo, S. Baker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Ming Zhao, Alex Sparreboom, A. Wolff, 2004, Clinical Cancer Research.

Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.

R. Hales, D. Ettinger, B. Levy, 2022, Clinical lung cancer.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

A. Drilon, S. Gettinger, L. Crinò, 2019, The Lancet. Oncology.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)

C. Dooms, M. Socinski, J. Riess, 2021, Clinical Trials.

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.

G. Rosner, V. Velculescu, J. Wolchok, 2016 .

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic immune checkpoint inhibitor pneumonitis

C. Lin, J. Taube, L. Yarmus, 2020, Journal for immunotherapy of cancer.

CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

J. Brahmer, 2012 .

An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis

R. Hales, J. Feliciano, J. Naidoo, 2022, Current oncology.

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.

D. Ettinger, G. Otterson, J. Feliciano, 2020, JAMA oncology.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

F. Marincola, P. Ascierto, M. Atkins, 2020, Journal for ImmunoTherapy of Cancer.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Matthew J. Frigault, J. Sosman, M. Ernstoff, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Reply to D.L. Kimpel et al.

M. Suarez‐Almazor, J. Brahmer, J. A. Thompson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Modality Treatment of Small-Cell Lung Cancer

D. Ettinger, L. Kleinberg, J. Brahmer, 2003 .

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)

T. Lynch, Priya Kumar, S. Teng, 2008 .

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

M. Socinski, G. Scagliotti, R. Govindan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

M. Socinski, L. Tye, S. Novello, 2010, British Journal of Cancer.

Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study

M. Socinski, R. Govindan, L. Tye, 2007 .

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

D. Ettinger, V. Anagnostou, B. Levy, 2022, The oncologist.

Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Y. Shentu, A. Tafreshi, M. O'Brien, 2017 .

Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599.

D. Carbone, H. Lenz, W. Zhang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042.

Y. Hosomi, H. Saka, E. Felip, 2019, Annals of Oncology.

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

S. Peters, E. Felip, H. Borghaei, 2017 .

Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).

R. Gray, J. Schiller, A. Dowlati, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.

P. Ascierto, M. Ahn, P. Ott, 2017 .

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S. Ou, M. Ahn, N. Segal, 2016 .

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: an Observational, Pharmacovigilance Study.

Sewon Kang, N. LeBoeuf, M. Alphonse, 2022, The Journal of investigative dermatology.

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team

J. Naidoo, Laura C. Cappelli, J. Brahmer, 2022, Journal of Cancer Research and Clinical Oncology.

Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.

David R. Jones, V. Rusch, V. Velculescu, 2017 .

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

N. Girard, K. O'Byrne, S. Ramalingam, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern

J. Taube, L. Diaz, C. Drake, 2017, The American journal of surgical pathology.

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis

Ami A. Shah, E. Lipson, V. Anagnostou, 2021, RMD Open.

PD-1-targeted immunotherapy: recent clinical findings.

J. Brahmer, 2012, Clinical advances in hematology & oncology : H&O.

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

David R. Jones, K. Schuebel, M. Brock, 2021, Nature.

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).

D. Heron, J. Luketich, S. Dacic, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

P. Ascierto, Rajeev Sharma, J. Sosman, 2021, Journal for ImmunoTherapy of Cancer.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

D. Leaf, M. Troxell, J. Wolchok, 2016, Kidney international.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Raoul Tibes, Glen J Weiss, C. Rudin, 2009, The New England journal of medicine.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

W. Guo, M. Socinski, Kwok-Kin Wong, 2013, Clinical Cancer Research.

NCCN: Continuing Education

Matthew J. Frigault, J. Sosman, M. Ernstoff, 2019 .

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

J. Taube, A. Klein, Lieping Chen, 2014, Clinical Cancer Research.

Emerging treatments for choroidal metastases.

J. Handa, J. Brahmer, Connie J. Chen, 2011, Survey of ophthalmology.

Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.

A. Wolff, M. Carducci, R. Donehower, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Alterations of immune response of non-small cell lung cancer with Azacytidine

Peter A. Jones, C. Zahnow, P. Laird, 2013, Oncotarget.

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

J. Taube, C. Drake, E. Lipson, 2012, Clinical Cancer Research.

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Ami A. Shah, E. Lipson, J. Albayda, 2016, Annals of the rheumatic diseases.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The emerging role of epigenetic therapeutics in immuno-oncology

S. Baylin, M. Vaz, J. Brahmer, 2019, Nature Reviews Clinical Oncology.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

M. Kris, J. Minna, I. Wistuba, 2017, Clinical Cancer Research.

Genome-wide cell-free DNA fragmentation in patients with cancer

H. Nielsen, R. Scharpf, C. Andersen, 2019, Nature.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response

Jamie B. Spangler, J. Taube, Hongkai Ji, 2022, bioRxiv.

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

David R. Jones, K. Schuebel, M. Brock, 2021, Nature.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

D. Ettinger, A. Jimeno, M. Hidalgo, 2008, Cancer Chemotherapy and Pharmacology.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Checkpoint Therapy in Non–Small Cell Lung Cancer

J. Brahmer, K. Marrone, 2016, Cancer journal.

Persistent mutation burden drives sustained anti-tumor immune responses

V. Velculescu, R. Karchin, V. Anagnostou, 2023, Nature Medicine.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Ludmila V. Danilova, L. Cope, K. Kinzler, 2019, Journal of Immunotherapy for Cancer.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Adith S. Arun, H. Nielsen, R. Scharpf, 2021, Nature Communications.

M. Suarez‐Almazor, X. Mariette, M. Callahan, 2020, Nature Reviews Disease Primers.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

M. Provencio, J. Penrod, F. Franke, 2019, European journal of cancer.

Epigenetic therapy inhibits metastases by disrupting premetastatic niches

C. Zahnow, J. Margolick, S. Baylin, 2020, Nature.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, Thomas J Smith, Gregory J Riely, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

E. Felip, L. Crinò, E. Vokes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma

J. Taube, Hongkai Ji, M. Hellmann, 2021, Journal for ImmunoTherapy of Cancer.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer

G. Rosner, V. Velculescu, J. Taube, 2016 .

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

Lisa M Haley, J. Eshleman, Ming-Tseh Lin, 2016, Oncotarget.

Genome-wide cell-free DNA fragmentation in patients with cancer

H. Nielsen, R. Scharpf, C. Andersen, 2019, Nature.

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

J. Taube, S. Broderick, P. Illei, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

David R. Jones, G. Rosner, M. Brock, 2020, Journal for ImmunoTherapy of Cancer.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

C. Rudin, A. Jimeno, N. Senzer, 2013, British Journal of Cancer.

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

C. Rudin, M. Ratain, Soma Das, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Jing Li, Manuel Hidalgo, Alex Sparreboom, 2007, Cancer biology & therapy.

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

S. Gettinger, P. Paik, S. Ramalingam, 2015 .

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

A. Venkatesan, K. Kinzler, C. Bettegowda, 2021, Journal for ImmunoTherapy of Cancer.

Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care

Richard D Moore, J. Herman, S. Baylin, 2006, Journal of acquired immune deficiency syndromes.

Imaging δ- and μ-Opioid Receptors by PET in Lung Carcinoma Patients

M. Brock, R. Dannals, H. Ravert, 2007 .

Clinical mutational profiling of 1006 lung cancers by next generation sequencing.

Lisa M Haley, J. Eshleman, Ming-Tseh Lin, 2017, Oncotarget.

Targeting the immune system for management of NSCLC: the revival?

J. Vansteenkiste, J. Brahmer, M. Reck, 2013, Current Respiratory Care Reports.

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

J. Schiller, A. Sandler, J. Brahmer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

J. Brahmer, S. Ulahannan, 2011, Cancer investigation.

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter

D. Ettinger, J. Brahmer, R. Juergens, 2007, Cancer Chemotherapy and Pharmacology.

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

What lies within: novel strategies in immunotherapy for non-small cell lung cancer.

K. Reiss, P. Forde, J. Brahmer, 2013, The oncologist.

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer

C. Obasaju, D. Ettinger, K. Kelly, 2004, Clinical Cancer Research.

Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

S. Ramalingam, J. Schiller, A. Sandler, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy for advanced stage non-small cell lung cancer.

A. Fathi, J. Brahmer, 2008, Seminars in thoracic and cardiovascular surgery.

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

R. Gray, S. Ramalingam, J. Schiller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Ami A. Shah, E. Lipson, J. Naidoo, 2019, Annals of the rheumatic diseases.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2019, European journal of cancer.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

A. Tafreshi, M. Pietanza, M. O'Brien, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2016, Clinical lung cancer.

Immunotherapy in the treatment of non-small cell lung cancer.

B. Cho, R. Soong, R. Soo, 2014, Lung cancer.

Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009 .

[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

“Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?”

J. Brahmer, C. Hann, 2007, Current treatment options in oncology.

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis

J. Schiller, A. Dowlati, A. Sandler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

J. Siegfried, S. Novello, J. Brahmer, 2018 .

Malignancy-Related Effusions

L. Fashoyin-Aje, J. Brahmer, Lola A. Fashoyin-Aje, 2020 .

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

P. Hwu, J. Wigginton, A. Gupta, 2012 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

R. Herbst, M. Truong, M. Carducci, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Y. Hosomi, Yi-long Wu, H. Saka, 2019, Lung cancer.

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

J. Naidoo, J. Brahmer, B. Wills, 2018, Current Treatment Options in Oncology.

D. Feller-Kopman, Douglas B. Johnson, M. Nishino, 2020, Journal for immunotherapy of cancer.

Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes.

D. Ettinger, J. Feliciano, J. Naidoo, 2019, Journal of Clinical Oncology.

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Kwok-Kin Wong, Zhi Tan, John V. Heymach, 2018, Nature Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Non‐small cell lung cancer: Adjuvant and neo‐adjuvant chemotherapy

D. Ettinger, J. Brahmer, 2007, Respirology.

KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).

Edward S. Kim, M. O'Brien, J. Brahmer, 2015 .

PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.

S. Ramalingam, V. Anagnostou, H. Borghaei, 2020 .

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

M. Socinski, G. Scagliotti, R. Govindan, 2009, British Journal of Cancer.

PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024

A. Tafreshi, M. O'Brien, J. Brahmer, 2017 .

Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer

Hao Wang, D. Laheru, C. Paller, 2023, Cancer research communications.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

R. Scharpf, V. Velculescu, V. Anagnostou, 2019, Cancer research.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

D. Gerber, J. Schiller, D. Ahn, 2013, British Journal of Cancer.

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.

V. Anagnostou, M. Hellmann, J. Chaft, 2019, Journal of Clinical Oncology.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

K. Reiss, P. Forde, J. Brahmer, 2014, Immunotherapy.

Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?

J. Brahmer, 2014, Seminars in oncology.

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

D. Pardoll, J. Brahmer, Drew M. Pardoll, 2013, Cancer Immunology Research.

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer

V. Anagnostou, J. Brahmer, 2015, Clinical Cancer Research.

Reply: Regulatory T cells—an important target for cancer immunotherapy

C. Drake, E. Lipson, J. Brahmer, 2014, Nature Reviews Clinical Oncology.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Jun O. Liu, D. Ettinger, C. Rudin, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab in NSCLC: latest evidence and clinical potential

B. Cho, R. Soo, J. Brahmer, 2015, Therapeutic advances in medical oncology.

Nivolumab: targeting PD-1 to bolster antitumor immunity.

E. Lipson, J. Brahmer, H. Hammers, 2015, Future oncology.

Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer

J. Brahmer, Deepa Rangachari, 2013, Current Treatment Options in Oncology.

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

C. Drake, I. Lowy, A. Korman, 2008 .

Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team

J. Naidoo, Laura C. Cappelli, J. Brahmer, 2022, Journal of Cancer Research and Clinical Oncology.

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

R. Gray, J. Schiller, David H. Johnson, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A. Tafreshi, M. O'Brien, J. Brahmer, 2017, The Lancet. Oncology.

Immune Checkpoint Modulation for Non–Small Cell Lung Cancer

Aurélien Marabelle, S. Gettinger, J. Soria, 2015, Clinical Cancer Research.

Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.

P. LoRusso, S. Piha-Paul, Christina Wu, 2019 .

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC

R. Wahl, M. Knopp, C. Rudin, 2017, EJNMMI Research.

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30

Sydney M. Dy, Antonio C. Wolff, Albert W. Wu, 2010, Quality of Life Research.

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice

Sydney M. Dy, Antonio C. Wolff, Albert W. Wu, 2007, Supportive Care in Cancer.

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

V. Velculescu, R. Karchin, P. Illei, 2021, Nature Medicine.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

L. Urban, K. O'Byrne, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future

J. Brahmer, R. Juergens, 2005, Current oncology reports.

Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions

J. Brahmer, T. Lin, 2004, Current oncology reports.

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer

G. Rosner, D. Ettinger, E. Gabrielson, 2018, The oncologist.

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

M. Suarez‐Almazor, M. Atkins, M. Pietanza, 2023, Journal for ImmunoTherapy of Cancer.

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019 .

144TiPCheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

K. O'Byrne, S. Ramalingam, M. Hellmann, 2017 .

Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.

R. Hales, S. Broderick, Stephen C. Yang, 2021, Lung cancer.

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

N. Girard, S. Broderick, T. Mitsudomi, 2022, Cancer Research.

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers

A. Venkatesan, C. Bettegowda, E. Lipson, 2020 .

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

J. Taube, C. Drake, Lieping Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen

T. Dang, P. Massion, R. Herbst, 2009, Journal of Thoracic Oncology.

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2018, Clinical Trials.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

D. Heron, J. Luketich, S. Dacic, 2013, Lung cancer.

A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

C. Schumann, S. Gettinger, Gregory Riely, 2012 .

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients.

M. Brock, R. Dannals, H. Ravert, 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%

A. Tafreshi, M. Pietanza, M. O'Brien, 2017 .

Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.

C. Drake, I. Lowy, A. Korman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.

E. Lipson, J. Brahmer, E. Nakajima, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.

J. Brahmer, J. Klamerus, 2008, Clinical lung cancer.

OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

K. Politi, R. Doebele, A. Tsao, 2017 .

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, S. Gettinger, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Using Immune Checkpoint Inhibitors in Lung Cancer.

J. Brahmer, K. Marrone, 2016, Oncology.

Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057

H. Dastani, R. Gralla, J. Penrod, 2016 .

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2020 .

Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer.

J. Brahmer, 2016, Clinical advances in hematology & oncology : H&O.

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.

H. Dastani, R. Gralla, J. Penrod, 2018, European journal of cancer.

Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials

Moon S. Chen, M. Fouad, E. Hawk, 2014, Cancer.

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.

D. Ettinger, B. Levy, J. Brahmer, 2019, Cancer treatment and research communications.

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503

D. Carbone, Adriana L. Gonzalez, J. Schiller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

J. Kolesar, J. Schiller, J. Brahmer, 2014, European journal of cancer.

A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

E. Vokes, N. Rizvi, P. Baas, 2015 .

Pembrolizumab in Non-Small-Cell Lung Cancer.

J. Brahmer, M. Reck, 2017, The New England journal of medicine.

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Y. Shentu, A. Tafreshi, M. O'Brien, 2016 .

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

S. Gettinger, N. Rizvi, M. Hellmann, 2015 .

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

M. Ahn, N. Segal, A. Gupta, 2017 .

OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

Clinical mutational profiling of 1006 lung cancers by next generation sequencing

Lisa M Haley, J. Eshleman, Ming-Tseh Lin, 2017, Oncotarget.

Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?

J. Brahmer, R. Juergens, 2007, Current oncology reports.

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival

D. Ettinger, J. Brahmer, M. Yarchoan, 2015, Cureus.

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

S. Ramalingam, M. Hellmann, H. Borghaei, 2020 .

Symptoms, supportive care needs, and function in cancer patients: how are they related?

A. Wu, A. Wolff, C. Snyder, 2008, Quality of Life Research.

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).

R. Robles, T. Lynch, D. Spigel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

R. Scharpf, D. Ettinger, V. Velculescu, 2023, bioRxiv.

Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36

J. Dancey, K. Ding, G. Nicholas, 2023, Cancer Research.

A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer

I. Pastan, E. Jaffee, D. Laheru, 2008 .

P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC

S. Broderick, T. Mitsudomi, K. Kerr, 2018, Journal of Thoracic Oncology.

Derivation of CD8+ T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis

S. Baylin, G. Hostetter, V. Velculescu, 2023, iScience.

Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy.

Peter A. Jones, C. Zahnow, S. Baylin, 2013 .

Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.

R. Hales, E. Lipson, A. Bydon, 2023, Journal of neurosurgery. Spine.

Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Concordance of cancer patients’ function, symptoms, and supportive care needs

A. Wu, A. Wolff, C. Snyder, 2009, Quality of Life Research.

OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC

M. Provencio, J. Penrod, F. Franke, 2018, Journal of Thoracic Oncology.

Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.

R. Scharpf, D. Ettinger, V. Velculescu, 2020 .

Effectiveness of bevacizumab exposure beyond disease progression in patients with non–small‐cell lung cancer: analyses of the ARIES observational cohort study

A. Wozniak, D. Spigel, J. Brahmer, 2016, Pharmacoepidemiology and drug safety.

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

S. Ou, K. Steele, M. Rebelatto, 2016 .

Appendix: Supplemental Figures

Peter A. Jones, C. Zahnow, P. Laird, 2020, Deserter Country.

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

N. Girard, S. Broderick, K. Kerr, 2017 .

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2018 .

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human immunodeficiency virus and lung cancer: differences in presentation and clinical course.

Richard D Moore, J. Herman, S. Baylin, 2005 .

Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

C. Zahnow, S. Baylin, R. Scharpf, 2017 .

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

K. O'Byrne, M. Hellmann, H. Borghaei, 2021, Annals of Oncology.

Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.

D. Ettinger, C. Rudin, Martin R. Weber, 2009, The oncologist.

Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.

C. Drake, J. Wigginton, L. Chow, 2013 .

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA

V. Velculescu, L. Diaz, M. Popoli, 2016, Clinical Cancer Research.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

J. Taube, C. Drake, Lieping Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

C. Drake, E. Lipson, J. Brahmer, 2014, Nature Reviews Clinical Oncology.

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

M. Socinski, G. Scagliotti, R. Govindan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

K. Politi, R. Doebele, Shuxing Zhang, 2018, Nature Medicine.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

R. Scharpf, V. Velculescu, V. Anagnostou, 2018, Cancer research.

A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma

W. Ma, D. Laheru, D. Armstrong, 2007 .

Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer.

G. Bepler, M. Schell, S. Gadgeel, 2013 .

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, N. Rizvi, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Alterations of immune response of non-small cell lung cancer with Azacytidine

C. Zahnow, D. Weisenberger, S. Baylin, 2013, Oncotarget.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

C. Lin, D. Ettinger, L. Yarmus, 2019, The Journal of clinical investigation.

Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.

Christopher M. Jackson, D. Ettinger, S. Srivastava, 2021, Journal of neurosurgery.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019

M. Wahidi, J. Sosman, M. Lacouture, 2019 .

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

P. Forde, J. Brahmer, R. Kelly, 2014, Clinical Cancer Research.

Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer

H. Borghaei, J. Brahmer, Joan H. Schiller, 2024, The oncologist.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Ami A. Shah, K. F. Moseley, E. Lipson, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer

C. Rudin, M. Kris, C. Azzoli, 2007 .

Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients

M. Hidalgo, M. Karlsson, S. Baker, 2005 .

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

J. Schiller, David H. Johnson, A. Sandler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials

Moon S. Chen, M. Fouad, E. Hawk, 2014, Cancer.

Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.

J. Nemunaitis, S. Ou, M. Ahn, 2018 .

DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.

M. Stockler, M. Zauderer, N. Pavlakis, 2021, Journal of Clinical Oncology.